• Je něco špatně v tomto záznamu ?

Blastic plasmacytoid dendritic cell neoplasm: First retrospective study in the Czech Republic

M. Cernan, T. Szotkowski, M. Hisemova, P. Cetkovsky, L. Sramkova, J. Stary, Z. Racil, J. Mayer, J. Sramek, P. Jindra, B. Visek, P. Zak, J. Novak, T. Kozak, T. Furst, T. Papajik,

. 2020 ; 67 (3) : 650-659. [pub] 20200217

Jazyk angličtina Země Slovensko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20025060

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with aggressive behavior and poor prognosis. We present the first retrospective analysis mapping its incidence and therapeutic outcomes in patients diagnosed and treated from 2000 to 2017 in the Czech Republic. The cohort comprised 14 patients (10 males, 4 females) with a median age at diagnosis of 39 years (range, 5-68 years). Initially, skin involvement was noted in 10 (71%) patients and bone marrow infiltration was present in 9 (64%). The first complete remission was achieved in 6/14 (43%) patients after acute lymphoblastic leukemia/lymphoma induction therapy and in 3/14 (21%) patients after acute myeloid leukemia regimen. Nine patients underwent allogeneic hematopoietic cell transplantation, with two patients achieving the first complete remission only after allogeneic transplantation. Patients undergoing allogeneic hematopoietic cell transplantation had longer overall survival than those treated without transplantation (the median survival over the period 16.4 vs. 8.1 months). Relapse of the disease was a significant predictor of mortality (p=0.05). Over the study period, patients' survival ranged from 3.3 to 44.2 months, with a median overall survival of 13 months. Our results revealed an effectivity of allogeneic hematopoietic cell transplantation on complete remission achievement in refractory/relapsed disease. The study aimed to present the actual data from the Czech Republic and thus contribute to a global understanding of BPDCN.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20025060
003      
CZ-PrNML
005      
20220505113843.0
007      
ta
008      
201125s2020 xo f 000 0|eng||
009      
AR
024    7_
$a 10.4149/neo_2020_190507N407 $2 doi
035    __
$a (PubMed)32064883
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xo
100    1_
$a Cernan, M $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic.
245    10
$a Blastic plasmacytoid dendritic cell neoplasm: First retrospective study in the Czech Republic / $c M. Cernan, T. Szotkowski, M. Hisemova, P. Cetkovsky, L. Sramkova, J. Stary, Z. Racil, J. Mayer, J. Sramek, P. Jindra, B. Visek, P. Zak, J. Novak, T. Kozak, T. Furst, T. Papajik,
520    9_
$a Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with aggressive behavior and poor prognosis. We present the first retrospective analysis mapping its incidence and therapeutic outcomes in patients diagnosed and treated from 2000 to 2017 in the Czech Republic. The cohort comprised 14 patients (10 males, 4 females) with a median age at diagnosis of 39 years (range, 5-68 years). Initially, skin involvement was noted in 10 (71%) patients and bone marrow infiltration was present in 9 (64%). The first complete remission was achieved in 6/14 (43%) patients after acute lymphoblastic leukemia/lymphoma induction therapy and in 3/14 (21%) patients after acute myeloid leukemia regimen. Nine patients underwent allogeneic hematopoietic cell transplantation, with two patients achieving the first complete remission only after allogeneic transplantation. Patients undergoing allogeneic hematopoietic cell transplantation had longer overall survival than those treated without transplantation (the median survival over the period 16.4 vs. 8.1 months). Relapse of the disease was a significant predictor of mortality (p=0.05). Over the study period, patients' survival ranged from 3.3 to 44.2 months, with a median overall survival of 13 months. Our results revealed an effectivity of allogeneic hematopoietic cell transplantation on complete remission achievement in refractory/relapsed disease. The study aimed to present the actual data from the Czech Republic and thus contribute to a global understanding of BPDCN.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a dendritické buňky $x patologie $7 D003713
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a hematologické nádory $x mortalita $x terapie $7 D019337
650    12
$a transplantace hematopoetických kmenových buněk $7 D018380
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a recidiva $7 D012008
650    _2
$a indukce remise $7 D012074
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a mladý dospělý $7 D055815
651    _2
$a Česká republika $7 D018153
655    _2
$a časopisecké články $7 D016428
700    1_
$a Szotkowski, T $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic.
700    1_
$a Hisemová, Miloslava $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. $7 xx0272596
700    1_
$a Cetkovsky, P $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
700    1_
$a Sramkova, L $u Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.
700    1_
$a Stary, J $u Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.
700    1_
$a Racil, Z $u Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic.
700    1_
$a Mayer, J $u Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic.
700    1_
$a Sramek, J $u Department of Hemato-Oncology, University Hospital Pilsen, Pilsen, Czech Republic.
700    1_
$a Jindra, P $u Department of Hemato-Oncology, University Hospital Pilsen, Pilsen, Czech Republic.
700    1_
$a Visek, B $u 4th Department of Internal Medicine - Hematology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic.
700    1_
$a Zak, P $u 4th Department of Internal Medicine - Hematology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic.
700    1_
$a Novak, J $u Department of Internal Medicine and Hematology, University Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Kozak, T $u Department of Internal Medicine and Hematology, University Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Furst, T $u Department of Mathematical Analysis and Application of Mathematics, Faculty of Science, Palacky University Olomouc, Olomouc, Czech Republic.
700    1_
$a Papajik, T $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic.
773    0_
$w MED00003470 $t Neoplasma $x 0028-2685 $g Roč. 67, č. 3 (2020), s. 650-659
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32064883 $y Pubmed
910    __
$a ABA008 $b A 1194 $c 659 $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20220505113837 $b ABA008
999    __
$a ok $b bmc $g 1599205 $s 1115746
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 67 $c 3 $d 650-659 $e 20200217 $i 0028-2685 $m Neoplasma $n Neoplasma $x MED00003470
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Možnosti archivace